# 2026 eCQM Flow eCQM Identifier: CMS136v15

NOTE: This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.


#### Follow-Up Care for Children Prescribed ADHD Medication

Percentage of children 6-12 years of age and newly prescribed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.

- a. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.
- b. Percentage of children who remained on ADHD medication for at least 210 treatment days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.


#### This eCQM is a patient-based measure

#### **Initial Population 1**



2026 eCQM Flow eCQM Identifier: CMS136v15

# Follow-Up Care for Children Prescribed ADHD Medication




Performance Rate 1 = Sample Calculation: Performance Rate 1	opulation 1
Numerator 1 (a <sup>1</sup> = 40 patients)	40
Denominator 1 (b <sup>1</sup> = 100 patients) - Denominator Exclusions 1 (x <sup>1</sup> = 20 patients)	= = 50 %

2026 eCQM Flow eCQM Identifier: CMS136v15

#### **Initial Population 2** Children 6 to 12 years of age as of the Intake Period No acute inpatient stay with a principal diagnosis Yes of mental, behavioral, or neurodevelopmental disorder during the Continuation and Maintenance Phase **Earliest** ADHD medication prescription during the Intake Period where the patient is not actively on ADHD Yes medication during the 120 days Do not include in prior, also known as **Initial Population 2 Denominator 2** Index Prescription Start Date (IPSD) **Equals Initial** Population 2 (100 patients) Do not include in Initial Population 2 Yes **Denominator Exclusions 2** Eligible encounter within 6 months prior to the IPSD including Hospice the IPSD care for any part of the measurement period Yes Denominator Exclusions 2 No (20 patients) Remained on Diagnosed the medication for with narcolepsy Yes at least 210 treatment days at any point in their during the 301-day period, history or during the beginning on the IPSD measurement through 300 days period after the **IPSD** No Go to Page 4

2026 eCQM Flow eCQM Identifier: CMS136v15



Sample Calculation: Population 2 Performance Rate 2 =	
Numerator 2 (a² = 40 patients)	40
Denominator 2 (b² = 100 patients) - Denominator Exclusions 1 (x² = 20 patients)	= = 50 %

# eCQM Identifier: CMS136v15 eCQM Title: Follow-Up Care for Children Prescribed ADHD Medication

**NOTE:** This flow diagram represents an overview of population criteria requirements. Refer to the eCQM specification for a complete list of data elements included in this measure and required for submission.

**Description:** Percentage of children 6 to 12 years of age and newly prescribed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.

- a. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.
- b. Percentage of children who remained on ADHD medication for at least 210 treatment days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

This eCQM is a patient-based measure.

# **eCQM Flow Narrative**

# **Initial Population 1**

Start by identifying the Initial Population 1, which includes children 6 to 12 years of age as of the Intake Period who had an Index Prescription Start Date (IPSD) and who had an eligible encounter within 6 months prior to the IPSD including the IPSD. IPSD is the earliest prescription date for an ADHD medication where the date is during the Intake Period and the patient is not actively on ADHD medication during the 120 days prior. Children are removed if they had an acute inpatient stay with a principal diagnosis of mental, behavioral or neurodevelopmental disorder during the Initiation Phase.

#### **Denominator 1**

Denominator 1 equals the Initial Population 1. In the sample calculation for population 1 provided at the end of the eCQM flow, Denominator 1 is equal to 100 patients.

#### **Denominator Exclusions 1**

The Denominator Exclusions 1 criteria identify a subset of the Denominator 1 population by excluding patients who are in hospice care for any part of the measurement period, and patients diagnosed with narcolepsy at any point in their history or during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 1 are equal to 20 patients.

#### Numerator 1

The Numerator 1 criteria identify a subset of the Denominator 1 population (that did not meet the Denominator Exclusions 1 criteria) by including patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase. In the sample calculation provided at the end of the eCQM flow, Numerator 1 is equal to 40 patients.

# Sample Calculation: Population 1

A sample calculation for population 1 is provided to help determine how the measure performance rate 1 is derived. The measure performance rate 1 is calculated by dividing the Numerator 1 (total equals 40 patients) by the difference between the Denominator 1 (total equals 100 patients) and the Denominator Exclusions 1 (total equals 20 patients), which is equal to a score of 50 percent.

# **Initial Population 2**

Continue by identifying the Initial Population 2, which includes children 6 to 12 years of age as of the Intake Period who had an Index Prescription Start Date (IPSD), an eligible encounter within 6 months prior to the IPSD including the IPSD, and remained on the medication for at least 210 treatment days during the 301-day period, beginning on the IPSD through 300 days after the IPSD. Children are removed if they had an acute inpatient stay with a principal diagnosis of mental, behavioral or neurodevelopmental disorder during the Continuation and Maintenance Phase.

# **Denominator 2**

Denominator 2 equals the Initial Population 2. In the sample calculation for population 2 provided at the end of the eCQM flow, Denominator 2 is equal to 100 patients.

### **Denominator Exclusions 2**

The Denominator Exclusions 2 criteria identify a subset of the Denominator 2 population by excluding patients who are in hospice care for any part of the measurement period and patients diagnosed with narcolepsy at any point in their history or during the measurement period. In the sample calculation provided at the end of the eCQM flow, the Denominator Exclusions 2 are equal to 20 patients.

#### Numerator 2

The Numerator 2 criteria identify a subset of the Denominator 2 population (that did not meet the Denominator Exclusions 2 criteria) by including patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase and at least two follow-up visits on different dates of service during the 31-300 days after the IPSD. In the sample calculation provided at the end of the eCQM flow, Numerator 2 is equal to 40 patients.

# **Sample Calculation: Population 2**

A sample calculation for population 2 is provided to help determine how the measure performance rate 2 is derived. The measure performance rate 2 is calculated by dividing the Numerator 2 (total equals 40 patients) by the difference between the Denominator 2 (total equals 100 patients) and the Denominator Exclusions 2 (total equals 20 patients), which is equal to a score of 50 percent.